Here we provide the proof-of-concept for an unconventional and effective nanotechnology-based inhalation approach for delivery of a synthetic miRNA mimic via biocompatible and biodegradable calcium phosphate-based nanoparticles (CaPs) preferentially to cardiomyocytes without significant accumulation in other myocardial cells or organs.
Nano-miR-133a Replacement Therapy Blunts Pressure Overload-Induced Heart Failure
Modica J.;Di Mauro V.;Carullo P.;Nemska S.;Condorelli G.;Iafisco M.;Miragoli M.;Catalucci D.
2021
Abstract
Here we provide the proof-of-concept for an unconventional and effective nanotechnology-based inhalation approach for delivery of a synthetic miRNA mimic via biocompatible and biodegradable calcium phosphate-based nanoparticles (CaPs) preferentially to cardiomyocytes without significant accumulation in other myocardial cells or organs.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
